VNDA Vanda Pharmaceuticals Inc.
Legal ·
A Delaware federal court granted summary judgment of non-infringement for Teva and Apotex in September 2026. Vanda is weighing its options, and its 10-Q also reports a DOJ notice and new generic-drug suits.
We have not published a story on Vanda Pharmaceuticals yet. When there is news, it will appear here.
Vanda Pharmaceuticals is a global biopharmaceutical company focused on developing and commercializing innovative therapies for high unmet medical needs, applying its pharmacogenetics and pharmacogenomics expertise. Its commercial portfolio comprises four products. FANAPT (iloperidone) is approved for schizophrenia and for the acute treatment of manic or mixed episodes associated with bipolar I disorder. HETLIOZ (tasimelteon) is the first FDA-approved treatment for Non-24-Hour Sleep-Wake Disorder (Non-24) and for nighttime sleep disturbances in Smith-Magenis syndrome. PONVORY (ponesimod) treats relapsing forms of multiple sclerosis, and NEREUS (tradipitant) is marketed for prevention of vomiting induced by motion. In development are a long-acting injectable Fanapt formulation, Bysanti (milsaperidone), the active metabolite of Fanapt, and imsidolimab, an IL-36R antagonist for generalized pustular psoriasis. The company is headquartered in Washington, D.C.
| Product or program | What it is | Stage |
|---|---|---|
| FANAPT (iloperidone) | Treatment for schizophrenia and bipolar I manic or mixed episodes | approved in the US |
| HETLIOZ (tasimelteon) | Melatonin agonist for Non-24 and sleep disturbances in Smith-Magenis syndrome | approved in the US |
| PONVORY (ponesimod) | Treatment for relapsing forms of multiple sclerosis | commercial product in the US and Canada |
| NEREUS (tradipitant) | Prevention of vomiting induced by motion | commercial product |
| Bysanti (milsaperidone) | Active metabolite of Fanapt for bipolar I disorder, schizophrenia and major depressive disorder | in development |
| imsidolimab | IL-36R antagonist for generalized pustular psoriasis | in development |
| Line | FY2025 | FY2024 |
|---|---|---|
| Revenue | $216.1 million | $198.8 million |
| Research and development | $109.3 million | $74.4 million |
| Net income (loss) | -$220.5 million | -$18.9 million |
| Cash from operations | -$109.4 million | -$15.8 million |
| Cash and equivalents | $84.9 million | $102.3 million |
Our latest story on this, dated Oct 29, 2026: "Court rules for Teva and Apotex in Vanda's HETLIOZ patent suits". The story links the filing or release it is based on. Read the story.
Vanda Pharmaceuticals Inc. trades under the ticker VNDA on NASDAQ.
Vanda Pharmaceuticals Inc. is listed on NASDAQ. Our directory also records these other listings: GETTEX:VM4; LS:A0JJT3; LSE:0LKB; LSX:A0JJT3.
The SEC Central Index Key (CIK) for Vanda Pharmaceuticals Inc. is 1347178. Its filings are on SEC EDGAR.
60,462,687 shares as of 2026-07-30, per the cover page of its 10-Q filed 2026-08-06.
Our directory records Vanda Pharmaceuticals Inc. under United States.
Our directory classifies Vanda Pharmaceuticals Inc. as: Pharmaceuticals: Major. This is a directory classification, not a description of the pipeline.
The ISIN recorded for Vanda Pharmaceuticals Inc. is US9216591084.
aibio.space lists Vanda Pharmaceuticals Inc. among 2,820 public biotech companies and publishes its news here as stories appear.
SEC records list its state or country of incorporation as DE.
Vanda Pharmaceuticals is a global biopharmaceutical company focused on developing and commercializing innovative therapies for high unmet medical needs, applying its pharmacogenetics and pharmacogenomics expertise. Its commercial portfolio comprises four products.
FANAPT (iloperidone): Treatment for schizophrenia and bipolar I manic or mixed episodes Stage: approved in the US.
HETLIOZ (tasimelteon): Melatonin agonist for Non-24 and sleep disturbances in Smith-Magenis syndrome Stage: approved in the US.
$216.1 million for the fiscal year ended Dec 31, 2025, as reported to the SEC.
Vanda Pharmaceuticals Inc. reported a net loss of $220.5 million for the fiscal year ended Dec 31, 2025, and used $109.4 million of cash in operations, per its annual report to the SEC.
Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction
aibio